title: COLAL-PRED Alizyme.
abstract: COLAL-PRED (prednisolone sodium metasulfobenzoate), which is targeted to the colon by COLAL colonic drug delivery technology, is being developed by Alizyme for the potential treatment of inflammatory bowel disease. Alizyme expect to initiate a phase III trial in 2005.
authors.affiliation: University of Chicago Medical Center, Department of Medicine, Gastroenterology & Nutrition, MC 9028, 5841 S Maryland Avenue, Chicago, IL 60637, USA. shanauer@medicine.bsd.uchicago.edu
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Hanauer
authors.forename: Miles
authors.initials: M
authors.lastname: Sparrow
mesh_terms: D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D011239:Prednisolone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
chemical_list: C013218:prednisolone 21-3-sulfobenzoate; D011239:Prednisolone